Clinical trials for Polycythaemia

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Polycythaemia. For all clinical trials, go to clinical trials search

This list shows clinical trials for Polycythaemia

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Polycythaemia
Title Recruitment status Location
An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF) Recruiting United Kingdom
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) Recruiting United Kingdom
Myeloproliferative Neoplasms: an In-depth Case-control Study Recruiting United Kingdom
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib Recruiting United Kingdom
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Recruiting United Kingdom
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Recruiting United Kingdom
The optimal management in monochorionic twins (OMMIT) study Recruiting United Kingdom
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Recruiting United Kingdom
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib Recruiting United Kingdom
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes Recruiting United Kingdom

Page last reviewed: 26/05/2016

Next review due: 31/10/2018